U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C14H15F2N3S.ClH
Molecular Weight 331.812
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NEPICASTAT HYDROCHLORIDE ANHYDROUS

SMILES

Cl.NCC1=CNC(=S)N1[C@H]2CCC3=C(F)C=C(F)C=C3C2

InChI

InChIKey=DIPDUAJWNBEVOY-PPHPATTJSA-N
InChI=1S/C14H15F2N3S.ClH/c15-9-3-8-4-10(1-2-12(8)13(16)5-9)19-11(6-17)7-18-14(19)20;/h3,5,7,10H,1-2,4,6,17H2,(H,18,20);1H/t10-;/m0./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C14H15F2N3S
Molecular Weight 295.351
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/25602710 https://www.ncbi.nlm.nih.gov/pubmed/24983834

Nepicastat (SYN-117) is a potent and selective inhibitor of dopamine-β-hydroxylase. This compound in Phase 2 of clinical trial for the treatment cocaine addiction and posttraumatic stress disorder.

CNS Activity

Curator's Comment: Nepicastat is direct, competitive inhibitor of DBH that does not chelate copper, can cross the blood–brain barrier

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
9.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
160 mg 1 times / day multiple, oral
Dose: 160 mg, 1 times / day
Route: oral
Route: multiple
Dose: 160 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Disulfiram attenuates drug-primed reinstatement of cocaine seeking via inhibition of dopamine β-hydroxylase.
2010-11
Effects of disulfiram and dopamine beta-hydroxylase knockout on cocaine-induced seizures.
2008-06
Synthesis and biological evaluation of novel, peripherally selective chromanyl imidazolethione-based inhibitors of dopamine beta-hydroxylase.
2006-02-09
Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase.
1997-08

Sample Use Guides

In Vivo Use Guide
Curator's Comment: https://clinicaltrials.gov/ct2/show/NCT01704196?term=NEPICASTAT&rank=3
Post Traumatic Stress Disorder: 120 mg/day Cocaine Dependence: Nepicastat 120 mg and 100 mg riboflavin (once per day) for 11 weeks
Route of Administration: Oral
In Vitro Use Guide
Nepicastat produced concentration-dependent inhibition of bovine and human dopamine-beta-hydroxylase activity. The calculated IC50s for nepicastat were 8.5+0.8 nM and 9.0+0.8 nM for the bovine and human enzyme, respectively.
Substance Class Chemical
Created
by admin
on Mon Mar 31 21:25:51 GMT 2025
Edited
by admin
on Mon Mar 31 21:25:51 GMT 2025
Record UNII
3WK068D17I
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
(S)-5-(AMINOMETHYL)-1-(5,7-DIFLUORO-1,2,3,4-TETRAHYDRO-2-NAPHTHALENYL)-1,3-DIHYDRO-2H-IMIDAZOLE-2-THIONE MONOHYDROCHLORIDE
Preferred Name English
NEPICASTAT HYDROCHLORIDE ANHYDROUS
Common Name English
2H-IMIDAZOLE-2-THIONE, 5-(AMINOMETHYL)-1-((2S)-5,7-DIFLUORO-1,2,3,4-TETRAHYDRO-2-NAPHTHALENYL)-1,3-DIHYDRO-, HYDROCHLORIDE (1:1)
Systematic Name English
Code System Code Type Description
SMS_ID
300000055542
Created by admin on Mon Mar 31 21:25:51 GMT 2025 , Edited by admin on Mon Mar 31 21:25:51 GMT 2025
PRIMARY
PUBCHEM
9840545
Created by admin on Mon Mar 31 21:25:51 GMT 2025 , Edited by admin on Mon Mar 31 21:25:51 GMT 2025
PRIMARY
EPA CompTox
DTXSID00168811
Created by admin on Mon Mar 31 21:25:51 GMT 2025 , Edited by admin on Mon Mar 31 21:25:51 GMT 2025
PRIMARY
FDA UNII
3WK068D17I
Created by admin on Mon Mar 31 21:25:51 GMT 2025 , Edited by admin on Mon Mar 31 21:25:51 GMT 2025
PRIMARY
CAS
170151-24-3
Created by admin on Mon Mar 31 21:25:51 GMT 2025 , Edited by admin on Mon Mar 31 21:25:51 GMT 2025
PRIMARY
Related Record Type Details
SOLVATE->ANHYDROUS
Related Record Type Details
ACTIVE MOIETY